Chassieu, France
April 16, 2020
AMOEBA (FR0011051598 - AMEBA),a pioneer of amoeba- based technologies for the biocide and plant protection markets has signed an evaluation and testing agreement with Syngenta (SYNGENTA), one of the world's leaders in agriculture.
Developing more environmentally friendly solutions
In response to the growing demand for effective and sustainable solutions against fungal diseases, Syngenta will test different concepts based on Amoeba's Willaertia magna C2c Makyamoeba lysate.
Amoeba's proprietary biocontrol technology will be integrated into exhaustive Syngenta trial protocols, to be conducted at several sites across Europe. Upon successful completion of this evaluation phase, the two parties could explore possible co-development and commercialization options for this novel technology.
"During the last few weeks, the growing interest in our biocontrol solution has materialized in the form of several partnerships for the evaluation of our amoeba lysate. New, alternative technologies against pathogens are currently in high demand, driven by the increasing need of new modes of action. We have demonstrated, through proprietary trials, the efficacy of our solution on vine downy mildew, potato late blight and bean rust. These new partnerships with global leaders enable Amoeba to develop new formulations and broaden the range of possible applications." Explains Fabrice Plasson, Chairman and CEO of Amoéba.
Amoéba points out that the company is still in the testing phase for its biocide and biocontrol applications and does not currently market any products.
About AMOÉBA :
Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1)on a global chemical biocide market for water treatment, evaluated at €21Bn (2)and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3)in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.
- : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
- : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets (3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK
Topics
Species
